Roche's Enicepatide Shows Roughly 16% Weight Loss in Mid-Stage Diabetes Trial

Roche said Tuesday that its experimental dual GLP-1/GIP receptor agonist, enicepatide, produced roughly 16% weight loss over approximately 12 months in a mid-stage trial involving obese or overweight adults with type 2 diabetes, according to a report from Seeking Alpha, which cited the company's announcement.

What Roche Reported

Seeking Alpha reported that enicepatide, also known by the development code CT-388, is a once-weekly injectable that acts at both the GLP-1 and GIP receptors. The weight-loss figure and treatment period were given as approximations — “roughly 16%” over “approximately 12 months” — rather than as precise, finalized trial statistics, so both numbers should be read as directional.

Separately, Roche's own press release, titled "Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity", confirms that the company characterized the trial outcome as positive and that the announcement was dated September 22, 2026. The title itself does not provide additional numerical detail beyond confirming a positive Phase II readout for the same drug and patient population described in the Seeking Alpha report.

About the Drug

Enicepatide is described in the sourced reporting as a dual GLP-1/GIP receptor agonist — a design that, on our reading of the reported mechanism, is intended to engage both receptors in patients with type 2 diabetes who are also overweight or obese. The available reporting states only that the drug is administered by weekly injection; it does not specify dose levels, titration schedules, or how enicepatide's dosing profile compares with other injectable options.

Reading the Numbers

In our view, a roughly 16% weight-loss result over about a year in a mid-stage trial would be a notable outcome if confirmed with full statistical detail. However, the currently available reporting does not include the trial's patient count, statistical confidence intervals, HbA1c changes, adverse-event rates, or how the result was measured against a placebo or active comparator arm. Without those details, enicepatide's Phase II performance cannot responsibly be ranked alongside other drugs in its class, and we have avoided doing so here because no verified comparative data appeared in the sourced reporting.

It is also worth noting that both figures central to this story, the 16% weight-loss estimate and the roughly 12-month duration, were presented by Seeking Alpha as approximate rather than as verbatim trial statistics. That distinction matters for anyone trying to assess the strength of the underlying data, since rounded figures in secondary reporting can understate or overstate precision relative to a company's full clinical dataset.

Bottom Line

Roche has publicly confirmed a positive Phase II outcome for enicepatide, and Seeking Alpha's reporting puts a rough number, about 16% weight loss over roughly a year, on that outcome for patients with type 2 diabetes who are overweight or obese. The figures are described as approximate in the available reporting, and no verified detail on comparative efficacy, safety profile, or next clinical steps was available at the time of this report. Investors and readers following the obesity and diabetes drug space should watch for more granular data releases from Roche before drawing firm conclusions about how enicepatide's profile compares with other therapies in development.